Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2020 | Discussing MRD testing with patients

William Wierda • 10 Sep 2020
SOHO 2020
Chronic Lymphocytic Leukemia Leukemia

William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the use of commercialized minimal residual disease (MRD) measurements and what this means for patients specifcally. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from William Wierda

A deep dive into BTK degraders for the treatment of CLL 9:39
A deep dive into BTK degraders for the treatment of CLL
William Wierda • 6 Feb 2025
Barriers to the implementation of MRD-guided treatment into CLL clinical practice 2:20
Barriers to the implementation of MRD-guided treatment into CLL clinical practice
William Wierda • 27 Sep 2024
The 2024 update to the NCCN guidelines for CLL/SLL: coming soon 1:37
The 2024 update to the NCCN guidelines for CLL/SLL: coming soon
William Wierda • 27 Sep 2024
The impact of liso-cel approval on the CLL treatment landscape and barriers to its use 1:44
The impact of liso-cel approval on the CLL treatment landscape and barriers to its use
William Wierda • 27 Sep 2024

Related Videos

HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML 8:00
HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
Jesse Tettero • 6 Dec 2025
POD36 as a prognostic marker and clinical tool in frontline CLL 3:03
POD36 as a prognostic marker and clinical tool in frontline CLL
Paul Hampel • 8 Dec 2025
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology 7:37
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology
David Swoboda • 5 Dec 2025
Recent advancements in the understanding of Richter’s transformation 1:00
Recent advancements in the understanding of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals